<?xml version="1.0" encoding="UTF-8"?>
<p>Telaprevir in combination with standard antiviral therapy against HCV bestowed rapid viral response and considerably declined the HCV RNA levels. Further, extensive studies are conducted to assess sustained virological response while administration of combinational therapy [
 <xref ref-type="bibr" rid="B49">49</xref>]. Telaprevir is the first drug against HCV presently in progress which exclusively blocks HCV NS3/4A serine protease.
</p>
